KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $13.2 million.

  • Acadia Pharmaceuticals' Share-based Compensation fell 49.63% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year decrease of 33.87%. This contributed to the annual value of $67.0 million for FY2024, which is 0.95% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Share-based Compensation is $13.2 million, which was down 8.09% from $14.3 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Share-based Compensation ranged from a high of $26.2 million in Q3 2024 and a low of $10.4 million during Q4 2024.
  • Moreover, its 3-year median value for Share-based Compensation was $14.8 million (2024), whereas its average is $15.7 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Share-based Compensation surged by 41.13% in 2024, and later crashed by 49.63% in 2025.
  • Acadia Pharmaceuticals' Share-based Compensation (Quarterly) stood at $12.9 million in 2021, then climbed by 11.91% to $14.4 million in 2022, then increased by 25.04% to $18.0 million in 2023, then tumbled by 42.02% to $10.4 million in 2024, then tumbled by 49.63% to $13.2 million in 2025.
  • Its Share-based Compensation was $13.2 million in Q3 2025, compared to $14.3 million in Q2 2025 and $11.4 million in Q1 2025.